Article Data

  • Views 1027
  • Dowloads 155

Original Research

Open Access Special Issue

Characteristics of microsatellite instability-high gynecologic cancer and efficacy of pembrolizumab: a single-institution experience

  • Tomoko Sakamoto Taniguchi1
  • Shinichi Komiyama1,*,
  • Masaru Nagashima1
  • Mineto Morita1

1Department of Obstetrics and Gynecology, Toho University Omori Medical Center, 143-8541 Tokyo, Japan

DOI: 10.31083/j.ejgo4204113 Vol.42,Issue 4,August 2021 pp.752-756

Submitted: 29 May 2021 Accepted: 05 July 2021

Published: 15 August 2021

(This article belongs to the Special Issue Immunotherapy for Gynecological Oncology)

*Corresponding Author(s): Shinichi Komiyama E-mail: shinkomiyama@gmail.com

Abstract

Objective: The aim of this study was to examine the frequency and characteristics of patients with gynecologic cancer with microsatellite instability (MSI)-high, as well as the efficacy of pembrolizumab in these patients, by reviewing the experience of a single institution that performs MSI testing. Methods: We retrospectively investigated the frequency and characteristics of MSI-high in patients with advanced or recurrent gynecologic cancer who underwent MSI testing at Toho University Omori Medical Center. As MSI testing, the distribution of microsatellite length at five microsatellite markers (BAT25, BAT26, NR21, NR24, and MONO27) was analyzed by multiplex polymerase chain reaction. We considered to be MSI-high if two or more microsatellite markers were positive. Among patients with MSI-high, we investigated the clinical course of those who received pembrolizumab. Results: MSI testing was performed on 51 patients, four of whom (7.8%) showed MSI-high. Two of the four patients had recurrent endometrial cancer (poorly differentiated endometrioid in one and moderate differentiated endometrioid + clear cell + serous in the other), one had advanced endometrial cancer (stage IVB, poorly differentiated endometrioid), and one had advanced ovarian cancer (stage IIIC, clear cell). No MSI-high was found in the other gynecological cancers. The rate of MSI-high was 15.0% (3/20) for endometrial cancer and 6.7% (1/15) for ovarian cancer. Of the four patients with MSI-high, two received pembrolizumab monotherapy. Both of these patients responded well and have maintained the response for more than 12 months. Discussion: This is the first real-world study investigating MSI-high in Japanese women with gynecologic cancer. MSI testing should be performed aggressively in clinical practice to identify patients with advanced and recurrent gynecologic cancers who can benefit from pembrolizumab.


Keywords

MSI-high; Endometrial cancer; Ovarian cancer; Gynecologic cancer; Pem-brolizumab

Cite and Share

Tomoko Sakamoto Taniguchi,Shinichi Komiyama,Masaru Nagashima,Mineto Morita. Characteristics of microsatellite instability-high gynecologic cancer and efficacy of pembrolizumab: a single-institution experience. European Journal of Gynaecological Oncology. 2021. 42(4);752-756.

References

[1] Baretti M, Le DT. DNA mismatch repair in cancer. Pharmacology & Therapeutics. 2018; 189: 45–62.

[2] Dudley JC, Lin M, Le DT, Eshleman JR. Microsatellite Instability as a Biomarker for PD-1 Blockade. Clinical Cancer Research. 2016; 22: 813–820.

[3] Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. New England Journal of Medicine. 2015; 372: 2509–2520.

[4] Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nature Reviews Cancer. 2012; 12: 252–264.

[5] Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017; 357: 409–413.

[6] Bonneville R, Krook MA, Kautto EA, Miya J, Wing MR, Chen H, et al. Landscape of Microsatellite Instability across 39 Cancer Types. JCO Precision Oncology. 2017; 5: 1–15.

[7] Bando H, Okamoto W, Fukui T, Yamanaka T, Akagi K, Yoshino

T. Utility of the quasi‐monomorphic variation range in unresectable metastatic colorectal cancer patients. Cancer Science. 2018; 109: 3411–3415.

[8] Patil DT, Bronner MP, Portier BP, Fraser CR, Plesec TP, Liu X. A Five-marker Panel in a Multiplex PCR Accurately Detects Microsatellite Instability-high Colorectal Tumors without Control DNA. Diagnostic Molecular Pathology. 2012; 21: 127–133.

[9] Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Rüschoff J, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. Journal of the National Cancer Institute. 2004; 96: 261–268.

[10] McMeekin DS, Tritchler DL, Cohn DE, Mutch DG, Lankes HA, Geller MA, et al. Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: an NRG Oncology/Gynecologic Oncology Group Study. Journal of Clinical Oncology. 2016; 34: 3062–3068.

[11] Postow MA, Callahan MK, Wolchok JD. Immune Checkpoint Blockade in Cancer Therapy. Journal of Clinical Oncology. 2015; 33: 1974–1982.

[12] Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. Journal of Clinical Oncology. 2020; 38: 1–10.

[13] Miller DS, Filiaci VL, Mannel RS, Cohn DE, Matsumoto T, Tewari KS, et al. Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209). Journal of Clinical Oncology. 2020; 38: 3841–3850.

[14] Makker V, Taylor MH, Aghajanian C, Oaknin A, Mier J, Cohn AL, et al. Lenvatinib Plus Pembrolizumab in Patients with Advanced Endometrial Cancer. Journal of Clinical Oncology. 2020; 38: 2981–2992.

[15] Cai KQ, Albarracin C, Rosen D, Zhong R, Zheng W, Luthra R, et al. Microsatellite instability and alteration of the expression of hMLH1 and hMSH2 in ovarian clear cell carcinoma. Human Pathology. 2004; 35: 552–559.

[16] Howitt BE, Strickland KC, Sholl LM, Rodig S, Ritterhouse LL, Chowdhury D, et al. Clear cell ovarian cancers with microsatel-lite instability: a unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression. Oncoimmunology. 2017; 6: e1277308.

[17] Lu KH, Broaddus RR. Endometrial Cancer. New England Journal of Medicine. 2020; 383: 2053–2064.

[18] Klempner SJ, Fabrizio D, Bane S, Reinhart M, Peoples T, Ali SM, et al. Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: a Review of Current Evidence. Oncologist. 2020; 25: e147–e159.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top